Noninvasive Subharmonic Aided Pressure Estimation of Portal Hypertension

PHASE4CompletedINTERVENTIONAL
Enrollment

178

Participants

Timeline

Start Date

April 6, 2015

Primary Completion Date

March 31, 2019

Study Completion Date

March 31, 2019

Conditions
Liver DiseasesPortal Hypertension
Interventions
DRUG

SHAPE measurement (Sonazoid ultrasoud contrast agent)

Three vials with 48 µl of Sonazoid (GE Healthcare, Oslo, Norway) microbubbles (6 ml) will be prepared and drawn into a 10 ml syringe, placed in a syringe pump. Sonazoid will be co-infused at a rate of 0.024 µl/kg body weight/minute (suspension infusion rate of 0.18 ml/kg/hour) together with a 0.9% NaCl solution infused at a rate of at least 2 ml/min.

Trial Locations (2)

19104

University of Pennsylvania, Philadelphia

19107

Thomas Jefferson University, Dept of Radiology, Philadelphia

All Listed Sponsors
collaborator

University of Pennsylvania

OTHER

collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

lead

Thomas Jefferson University

OTHER

NCT02489045 - Noninvasive Subharmonic Aided Pressure Estimation of Portal Hypertension | Biotech Hunter | Biotech Hunter